Clinical trial NCT02342977: Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:
Official title: Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Osteoarthritis
Rheumatoid Arthritis
Avascular Necrosis
Keywords: total hip arthroplasty
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: VA Office of Research and Development
First posted: 2015-01-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine how effect lacosamide is in reducing the amount of pain medication needed following a total hip arthroplasty. The study team hypothesizes that a single dose of lacosamide will reduce the amount of pain medication required after surgery. The study team plans to evaluate the amount of pain medication needed and quality of pain control during a subject's hospital stay and at their three month follow-up visit following their surgery.

Detailed description: All patients who agree to participate in this study will receive the same surgical and anesthetic techniques that are provided to all our patients undergoing this procedure at this institution. Post-operative treatment and therapy and follow-up will also be the same as any of our patients undergoing this procedure at this institution.

The only difference would be that patients would be randomized (determined by chance, like a flip of a coin) to either receive a single dose of lacosamide (100 mg by mouth) or placebo (sugar pill by mouth) before the surgical procedure. This would be the only experimental part of this study.

In addition, specific information will be collected throughout the patients care until discharged from the orthopedic clinic (approximately 3 months after the procedure). The collected information will include subject's age, race and ethnicity, sex, height, weight, American Society of Anesthesiologist physical status, total amount of opioid (pain medication) use, pain scores, nausea and vomiting, time spent in the post anesthesia care unit (time to discharge readiness), and discharge from the hospital. The patient's pain score and opioid use will be assessed during their follow-up at approximately 3 months (Note: all of the specific information collected is normally gathered or documented in our surgical patients' record). In addition, participants may withdraw from the study at any time.

The main goal of this study is to determine if lacosamide can reduce the amount of opioids required in patient's undergoing a total hip arthroplasty. Lacosamide is a FDA approved medication for the treatment of partial-onset seizures and is a man-made amino acid (usually are used as the building blocks from which proteins are made in the body) which block special proteins inby a change in the electricity that a cell may feel (voltage-gated sodium channel). Lacosamide is a new antiepileptic drug apparently lacking any major pharmacokinetic interactions (how the body affects a specific drug after administration, as well as the chemical changes of the substance in the body, and the effects and routes of excretion of the metabolites of the drug).

Lacosamide, carbamazepine and oxcarbazepine are known to block special proteins in the covering of cells which allow sodium into the cells when they are turned on by a change in the electricity that a cell may feel (voltage-gated sodium channel, NaV1.7). Lacosamide was chosen over carbamazepine and oxcarbazepine because it causes fewer side effects. Currently, lacosamide is being tested in patients with painful diabetic nerve pain. Further trials to identify lacosamide's potential in pain control and for other indications have been started.

Eligibility criteria: Inclusion Criteria:

* Patients will be eligible for participation if they are 18-70 years of age.
* Patients who have an American Society of Anesthesiologists physical status I-III.
* Patients who are scheduled for primary total hip arthroplasty.
* Any patients who are willing to comply with study requirements and agrees to be in the study.

Exclusion Criteria:

* A patient's refusal to participate.
* Inability to give consent.
* Any patients on a scheduled opioid regimen for pain greater than 3 months.
* Bleeding diathesis.
* Hypersensitivity to lacosamide or any component of the formulation (some formulation contains phenylalanine) and/or any drug allergies to any medications used in this study.
* Second- or third-degree atrioventricular (AV) block, sick sinus syndrome without pacemaker, sodium channelopathies (e.g., Brugada syndrome), myocardial ischemia, heart failure, and structural heart disease.
* Severe hepatic and or renal impairment.
* Pregnant or can become pregnant.
* Breast-Feeding.
* Have any suicidal thoughts, depression, or behavioral changes.
* Taking any antiepileptic medications.
* Any known seizure disorder (e.g. Lennox-Gastaut syndrome).
* Currently prescribed:

Carbamazepine Strong inhibitors of cytochrome P450-2C9 (Capecitabine; Delavirdine; floxuridine; Fluorouracil (Systemic); Gemfibrozil; Nicardipine; Sitaxentan; Sulfadiazine; Sulfissoxazole; Tegafur; Tolbutamide) Strong inhibitors of cytochrome P450-3A4 (Atazanavir; Boceprevir; Chloramphenicol; Clarithromycin; Cobicistat; Conivaptan; Darunavir; Delavirdine; Fosamprenavir; Indinavir; Itraconazole; Ketoconazole (Systemic); Lopinavir; Nefazodone; Nelfinavir; Nicardipine; Posaconazole; Ritonavir; Saquinavir; Telaprevir; Telithromycin; Voriconazole) Delavirdine Fosphenytoin Nicardipin Phenobarbital Phenytoin Ethinylestradiol

Primary outcomes:
measure: Opioid use in Post anesthesia care unit
timeFrame: 30 minutes to 2 hours after surgery
Secondary outcomes:
measure: Pain scores
timeFrame: Post operative Day #0 through hospital discharge (4 day average)
measure: Nausea and Vomiting
timeFrame: Post operative Day #0 through hospital discharge (4 day average)
measure: Total opioid use
timeFrame: Post operative Day #0 through hospital discharge (4 day average)
measure: Time to PACU discharge readiness
timeFrame: 30 minutes to 2 hours after surgery
measure: Pain scores and opioid use at 3 month discharge
timeFrame: At 3 month surgery follow up
measure: Time to hospital discharge
timeFrame: Post operative Day #0 through hospital discharge ( 4 day average )
measure: Possible side effects from Lacosamide
timeFrame: Post operative Day #0 through hospital discharge (4 day average)
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Richard L. Roudebush Veterans Affairs Medical Center
state: Indiana
Study officials:
affiliation: Richard L. Roudebush VA Medical Center
name: Bryan M Sakamoto, M.D., PhD
role: PRINCIPAL_INVESTIGATOR
References: